• Home
  • About Nanexa
    • Company
    • Management
    • Board
    • Our story
  • Pharmashell®
  • Projects
  • Investors
    • Financial reports
    • Press releases
    • Corporate governance
    • The Stock
    • Analysts
    • Calendar
  • Media
    • Pressreleases
    • Subscribe
    • Publications
    • Presentations
  • Contact
  • English
    • Swedish

Investors

  • Financial reports
  • Pressreleases
  • Corporate governance
    • Shareholders’ meeting
    • Nomination commitee
    • Board
    • Management
    • Auditor
    • Articles of association
  • The Stock
    • Ownership Structure
  • Analysts
  • Calendar

Financial reports

4 May, 2023

Nanexa publishes interim report for January – March 2023

3 May, 2023

Nanexa publishes annual report for 2022

16 February, 2023

Nanexa publishes year-end report for 2022

25 October, 2022

Nanexa publishes interim report for January – September 2022

26 August, 2022

Nanexa publishes interim report for January – June 2022

20 April, 2022

Nanexa publishes annual report for 2021

Nanexa publishes interim report for January – March 2022

17 February, 2022

Nanexa publishes year-end report for 2021

10 November, 2021

Nanexa publishes interim report for January – September 2021

20 August, 2021

Nanexa publishes interim report for January – June 2021

6 May, 2021

Interim report Q1 2021

18 February, 2021

Nanexa Year-end report 2020

Investors

  • Financial reports
  • Pressreleases
  • Corporate governance
    • Shareholders’ meeting
    • Nomination commitee
    • Board
    • Management
    • Auditor
    • Articles of association
  • The Stock
    • Ownership Structure
  • Analysts
  • Calendar

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others AstraZeneca.

CONTACT

Nanexa AB, Virdings Allé 2, SE-75450 Uppsala, Sweden
Phone: +46 (0) 18 100 300
E-mail: info@nanexa.se
Org nr. 556833-0285

Integritetspolicy
Integritetspolicy för aktieägare

  • English
  • Svenska